Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of PCV26 in Adults Aged 60 and Above
NCT06970756Phase 1Not yet recruiting
- Sponsor
- Zhifei Green Bamboo
- Start
- May 2025
- Primary completion
- Nov 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 26-valent pneumococcal conjugate vaccine in pneumococcal disease (2 arms), sponsored by Zhifei Green Bamboo. Primary endpoints: Solicited Adverse Events and Solicited Systemic Adverse Events. Planned start May 2025; status: not yet recruiting.
02
Drugs
26-valent pneumococcal conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT06970756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06970756.